Peking University First Hospital
Beijing, China
NCT Number: NCT07020949
The aim of this trial is to investigate the safety, tolerability, pharmacokinetics, and efficacy of THDBH120 injection in participants with T2DM. This study includes three multiple-ascending dose cohorts.
Looking for future studies?
Notify Me18 year–65 year
All sexes
Interventional
Phase 1
Beijing, China
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Participants received THDBH120 by subcutaneous injection.
Participants received placebo by subcutaneous injection.
Time frame: 78 days
Time frame: Day 1 Pre-dose through Day 43
Time frame: Day 1 Pre-dose through Day 43
Time frame: 43 days
Time frame: 78 days
Looking for future studies?
Notify MeTonghua Dongbao Pharmaceutical Co.,Ltd
Industry
Multiple Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of THDBH120 in Chinese Patients With T2DM: A Randomized, Bouble-Blind, Placebo-Controlled Phase Ib Trial
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07719621
CKD - Chronic Kidney Disease, Chronic Disease
Madrid, Spain
View Trial DetailsNCT06851962
Diabetes Mellitus, Diabetes Mellitus Type 2
Málaga, Spain
View Trial DetailsNCT07783451
Behavior, Diabetes Mellitus
Istanbul, Turkey (Türkiye)
View Trial DetailsNCT07513259
Body Weight, Diabetes Mellitus
Taichung, Taichung City, Taiwan
View Trial Details